We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Compassionate Use Decision Boosts Sovaldi’s Standing
EMA Compassionate Use Decision Boosts Sovaldi’s Standing
In a decision that expands Sovaldi’s market dominance, the European Medicines Agency (EMA) Friday approved compassionate use of the Gilead drug with ledipasvir to treat patients with hepatitis C genotype 1.